about
Cardiac-specific overexpression of caveolin-3 attenuates cardiac hypertrophy and increases natriuretic peptide expression and signalingNatriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic EventsClinical Significance of B-type Natriuretic Peptide in Heart FailureCardiac fibrosis in myocardial infarction-from repair and remodeling to regenerationNatriuretic hormone: the ultimate determinant of the preservation of external sodium balanceIn-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptideA human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions.Ventricular-arterial uncoupling in heart failure with preserved ejection fraction after myocardial infarction in dogs - invasive versus echocardiographic evaluationPlasma soluble corin in patients with heart failure.Cell surface protein disulfide isomerase regulates natriuretic peptide generation of cyclic guanosine monophosphate.Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets.Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activityCorin: new insights into the natriuretic peptide systemPharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects.Designer natriuretic peptides.Evolution of biomarker guided therapy for heart failure: current concepts and trial evidence.Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies.Influence of sex and hormone status on circulating natriuretic peptides.Efficacy of B-Type Natriuretic Peptide Is Coupled to Phosphodiesterase 2A in Cardiac Sympathetic Neurons.Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis.Caveolin and caveolae in age associated cardiovascular diseaseEvaluation of Short-Term Use of N-Acetylcysteine as a Strategy for Prevention of Anthracycline-Induced Cardiomyopathy: EPOCH Trial - A Prospective Randomized Study.The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment.Genetic Analysis of the Atrial Natriuretic Peptide Gene Polymorphisms among Essential Hypertensive Patients in Malaysia.Differential diagnosis of acute dyspnea: the value of B natriuretic peptides in the emergency department.Corin, atrial natriuretic peptide and hypertension.Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide.B-type natriuretic peptide as predictor of heart failure in patients with acute ST elevation myocardial infarction, single-vessel disease, and complete revascularization: follow-up study.C-type natriuretic peptide and natriuretic peptide receptor B signalling inhibits cardiac sympathetic neurotransmission and autonomic functionThe role of nesiritide in heart failure.Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation.Thirty years of research on atrial natriuretic factor: historical background and emerging concepts.Novel vasodilators in heart failure.Natriuretic peptides in cardiovascular diseases: current use and perspectivesA Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.Natriuretic Peptide system and cardiovascular diseaseCombining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure.Disposition and metabolism of [(14)C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects.Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis
P2860
Q24629099-6AD18D09-7A89-4B41-8CFD-A726AFAB8DD7Q26778333-A2270FAD-5195-43F2-9C72-8FB11F8484D0Q27005797-D061E150-17B6-460A-9008-F640D45D7F83Q28068468-E87D5568-A13E-4231-A357-5B121DFDC245Q28084992-D23254AE-F493-4093-A78B-5BE2F569CCF8Q28486215-D25932C3-C2F5-4CD0-91E8-A740488ECD9BQ33577067-A00DD6ED-57FC-4A7A-BE42-3DEF2928A2BFQ33619843-BD878299-491B-4A8D-A3DF-59FBD8FE6FB9Q33887635-CEC6651C-6287-4994-A0D7-DBB475262345Q34565711-9C3132FE-FF7D-4EC5-94F8-B8B2148E5BF9Q34605877-DD891A66-625A-408E-AE79-0C9392DC8A19Q34803094-1F3931DA-544B-4B68-ADA7-888BF6C5AED1Q34810998-D9CECD20-191B-44F9-A360-A73CA6EB706AQ35086433-B2261931-7042-4ADA-BB73-AF693904BE11Q35086479-C2353E40-BCDC-4841-9549-1C38BE93B2D0Q35139977-6F76B563-EAF9-43F4-B53F-56699F98D05DQ35203569-96345249-B4F6-4A2E-BD33-2958E8505A08Q35207706-3F6C59F2-9792-4926-8C9D-F8294B59E450Q35806196-B4680388-2CEA-4F32-B55F-2DD85EA6DA03Q36528021-DDF064B3-E5D9-414C-804D-7E002842799CQ36769820-95B5E048-2ED5-490A-B406-C2A13A9A7F1EQ36774710-44619B7D-D789-4C4D-B18F-AD11D87B295EQ36923138-F591F8C2-C98D-4BBF-837F-4C45979C3930Q37060619-C33CCCA7-EDCB-4A81-B463-34B24429D69AQ37229555-16C06079-12A8-42EA-9414-3D548DAC4D38Q37290787-2D358E26-A7E5-4FA8-9C50-52B0B67ABC1EQ37343367-7665976A-14A4-4128-B124-2E44B40A0CD0Q37396223-BCA47947-E85A-48A5-97EB-595224704F8AQ37505040-55268548-AFF3-440A-B401-5421E3F9256FQ37523958-BA09311A-33F3-4CE0-AA23-D21E7706FE1CQ37694008-2EE42226-A3CA-4B66-B630-C0510075FDC4Q37809401-E8410CAD-3C71-47A2-B59E-5FEFA151852CQ37889289-C40E7DD6-EA63-49B9-B5A0-F8AE86F7A5C3Q38072635-6BEB412D-11D6-49E0-8128-BC914E77E357Q38162429-B8F11144-A585-4ECC-B3BA-9E39AA5EFE25Q38655266-AEFAFBC6-1ADC-41F8-B15A-25F501F9382DQ39821577-951E6958-5CF1-4CAF-90B4-2AD74617ED00Q40000430-A2906F8F-E969-41EC-A4B3-874E7FC0B719Q40877863-F146EABC-EEFD-4CF0-A2EB-C1304255B4C5Q41770246-1F4036A3-8BB5-428E-ACD4-3E9E9100FADA
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Natriuretic peptides and therapeutic applications.
@ast
Natriuretic peptides and therapeutic applications.
@en
type
label
Natriuretic peptides and therapeutic applications.
@ast
Natriuretic peptides and therapeutic applications.
@en
prefLabel
Natriuretic peptides and therapeutic applications.
@ast
Natriuretic peptides and therapeutic applications.
@en
P2860
P1476
Natriuretic peptides and therapeutic applications.
@en
P2093
Candace Y W Lee
John C Burnett
P2860
P2888
P304
P356
10.1007/S10741-007-9016-3
P577
2007-06-01T00:00:00Z